HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): L. Henry Edmunds, Jr Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suzuki, Y. Articles by Edmunds, L. H. Search for Related Content PubMed PubMed Citation Articles by Suzuki, Y. Articles by Edmunds, L. H., Jr

J Thorac Cardiovasc Surg 1999;117:987-993
© 1999 Mosby, Inc.

CARDIOPULMONARY SUPPORT AND PHYSIOLOGY

PLATELET ANESTHESIA WITH NITRIC OXIDE WITH OR WITHOUT EPTIFIBATIDE DURING CARDIOPULMONARY BYPASS IN BABOONS

From the Harrison Surgical Research Laboratories, Department of Surgery, University of Pennsylvania School of Medicine, and the Sol Sherry Thrombosis Research Center, Department of Medicine, Temple University, Philadelphia.

Supported by HL 47186 from the National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Md.

Received for publication Sept 18, 1998. Revisions requested Nov 19, 1998. Revisions received Jan 5, 1999. Accepted for publication Jan 11, 1999. Address for reprints: L. Henry Edmunds, Jr, MD, Department of Surgery, Hospital of the University of Pennsylvania, 6 Silverstein, 3400 Spruce St, Philadelphia, PA 19104-4283.

Objective:This study tested the hypothesis that nitric oxide or nitric oxide and eptifibatide (Integrilin) reversibly inhibit platelet activation and consumption during cardiopulmonary bypass and rapidly restore platelet numbers and function after bypass.
Methods: Nitric oxide, a short-acting, reversible platelet inhibitor, was studied with and without eptifibatide, a short-acting, reversible glycoprotein IIb/IIIa inhibitor, in 21 baboons that underwent 60 minutes of normothermic cardiopulmonary bypass with peripheral cannulas. A control group, a group that received 80 ppm nitric oxide, and a group that received both nitric oxide and eptifibatide were studied. Blood samples were obtained at several time points to determine platelet count, aggregation in response to adenosine diphosphate, and levels of ß-thromboglobulin, prothrombin fragment 1.2, and thrombin-antithrombin complex. Template bleeding times were measured before and at 4 intervals after cardiopulmonary bypass.
Results: Both nitric oxide and the combination of the 2 drugs significantly attenuated platelet consumption, improved postbypass function, and reduced plasma ß-thromboglobulin release with respect to values in control animals. Both nitric oxide and the combination restored baseline bleeding times 55 minutes after cardiopulmonary bypass ended. No significant differences between nitric oxide and the combination were found for any measurement.
Conclusion: Nitric oxide with or without eptifibatide protects platelets during cardiopulmonary bypass and accelerates restoration of normal bleeding times after operation in a baboon model. Although nitric oxide and eptifibatide reversibly inhibit platelets by different mechanisms, in the absence of a wound no synergistic effect was demonstrated.

This article has been cited by other articles:

				C. M. Dyke, L. K. Jennings, G. Maier, C. Andreou, R. Daly, and M. R. Tamberella III Preoperative Platelet Inhibition With Eptifibatide During Coronary Artery Bypass Grafting With Cardiopulmonary Bypass Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 54 - 60. [Abstract] [PDF]

				L. H. Edmunds Jr and R. W. Colman Thrombin During Cardiopulmonary Bypass Ann. Thorac. Surg., December 1, 2006; 82(6): 2315 - 2322. [Abstract] [Full Text] [PDF]

				N. Kondo, Y. Suzuki, F. Wakayama, Y. Tamai, K. Ji, K. Fukui, and I. Fukuda Platelet Preservation With a Glycoprotein IIb/IIIa Inhibitor in a Porcine Cardiopulmonary Bypass Model Ann. Thorac. Surg., July 1, 2005; 80(1): 251 - 257. [Abstract] [Full Text] [PDF]

				Y. Hiramatsu, S. Homma, Y. Sato, S. Sato, K. Matsuzaki, O. Shigeta, and Y. Sakakibara Nafamostat Preserves Neutrophil Deformability and Reduces Microaggregate Formation During Simulated Extracorporeal Circulation Ann. Thorac. Surg., April 1, 2005; 79(4): 1326 - 1332. [Abstract] [Full Text] [PDF]

				L H. Edmunds Jr The evolution of cardiopulmonary bypass: lessons to be learned Perfusion, July 1, 2002; 17(4): 243 - 251. [Abstract] [PDF]

				J. H. Levy Platelet inhibitors and bleeding in cardiac surgical patients Ann. Thorac. Surg., August 1, 2000; 70(2): S9 - 11. [Abstract] [Full Text] [PDF]